Enid A. Haupt Chair in Surgery; Director, Hepatopancreatobiliary Fellowship Program; Director, Surgical Oncology Fellowship Program
As a surgical oncologist, I care for patients with benign and malignant (cancerous) diseases of the liver, bile duct, gallbladder, and pancreas. Many patients come to me with cancer that has spread, or metastasized, from the colon to the liver. I also have an interest in benign pancreatic tumors, which do not necessarily merit immediate removal but should be carefully watched for any changes that warrant surgery. The tumors that I treat are rare and many forms were once thought to be incurable. But because of innovative research, largely done at Memorial Sloan Kettering, and my close collaboration with our radiologists and medical oncologists, I can often offer patients a good chance at long-term survival and, in many cases, cure. Our team of five board-certified surgeons currently performs between 800 and 1,000 hepatopancreatobiliary operations annually.
At MSK, I am honored to hold the Enid A. Haupt Chair in Surgery. I also serve as Vice Chair of the MSK Research Council, which oversees all high-risk research protocols throughout the hospital. In addition, I am Program Director for two prestigious training fellowships, in Surgical Oncology and Hepatopancreatobiliary Surgery. Externally, I am Vice Chair of the National Comprehensive Cancer Network (NCCN) panel on Clinical Practice Guidelines in Hepatobiliary Cancers. For years I have worked closely with the NCCN to help shape and write these treatment guidelines that are today followed in the US and much of the world.
Since 1996, I have published more than 200 peer-reviewed journal articles. I am an invited member of the editorial board for Annals of Surgical Oncology, Digestive Surgery, and Hepatic Oncology, and am a reviewer for dozens of other specialty journals. I am also a member of many medical societies, in which I’ve held many leadership positions, and have lectured at close to 150 conferences for these and other organizations worldwide. In collaboration with MSK colleagues, I have been an editor on three textbooks: Surgical Management of Hepatobiliary and Pancreatic Disorders, and editions four and five of Blumgart’s Surgery of the Liver, Biliary Tract, and Pancreas.
I became a cancer surgeon in part because I find cancer a complicated and fascinating disease, but also because surgery is an exciting — and constantly evolving — treatment tool. Now, nearly two decades into my career, I find that what I value most are the relationships I have with my patients — working with them, often for many years, to find the best way to fight their disease with their particular needs and lifestyle in mind. Outside of work, I am a self-proclaimed family man and spend my free time with my wife and children.
- Clinical Expertise: Hepatobiliary Surgery; Surgical Oncology
- Languages Spoken: English
- Education: MD, Tufts University School of Medicine
- Residencies: University of Connecticut
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Surgery
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Michael I. D'Angelica
- A Phase I Study of Hepatic Arterial Infusion with Floxuridine, Dexamethasone, and Gemcitabine after Surgery for Liver Cholangiocarcinoma
- A Phase II Study of Hepatic Arterial Infusion and Intravenous Chemotherapy with or without Panitumumab in Patients with Normal KRAS with Resected Liver Metastases from Colorectal Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more